[AVING = Reporter] REV-MED (CEO Edward BG Shin) announced its participation in the 39th Korea International Medical & Hospital Equipment Show (KIMES 2024), held from March 14–17 at COEX, Seoul.
Pioneering Stem Cell and Regenerative Therapies
As a biotech company focused on stem cell research, REV-MED specializes in developing autologous stem cell therapy systems. With its proprietary technology, Novastem selectively extracts regenerative factors from human tissues, enabling treatments for anti-aging, tissue regeneration, and intractable brain diseases.
Novastem is a Class III medical device designed to harvest and centrifuge autologous bone marrow and blood, extracting concentrated live cells for reinfusion into the body. The product, approved in China and Japan, has established REV-MED as a leader in regenerative medical innovation.
Advanced Devices on Display
Hilthera 4.0: A laser device that treats deep tissue without causing burns or injuries, offering anti-inflammatory, pain relief, and swelling reduction effects. It is especially effective for joints, muscles, and bones.
Rewave: Making its debut at KIMES 2024, this aesthetic device utilizes solid-state microwave technology. Developed for the general aesthetics market, Rewave aims to expand access to advanced skin-care treatments.
Growth and Future Directions
REV-MED reported approximately KRW 10 billion ($7.5 million) in revenue for 2023, with 80% generated from international markets. The company is preparing to globally launch its Novastem anti-aging brand, alongside new technologies such as plasma-based orthopedic and aesthetic devices and ultrasound-powered lifting equipment.
A Vision for Innovation
A REV-MED representative stated, “Our participation in KIMES highlights our commitment to innovation in medical devices. Through challenges and unity, our team has achieved significant milestones, laying the groundwork for REV-MED to grow into a global leader.”
About KIMES: Since its inception in 1980, KIMES has been a driving force for the Korean medical industry, showcasing advancements in medical information systems, ultrasound devices, radiology, AI, robotics, and rehabilitation technologies.
[AVING = Reporter] REV-MED (CEO Edward BG Shin) announced its participation in the 39th Korea International Medical & Hospital Equipment Show (KIMES 2024), held from March 14–17 at COEX, Seoul.
Pioneering Stem Cell and Regenerative Therapies
As a biotech company focused on stem cell research, REV-MED specializes in developing autologous stem cell therapy systems. With its proprietary technology, Novastem selectively extracts regenerative factors from human tissues, enabling treatments for anti-aging, tissue regeneration, and intractable brain diseases.
Novastem is a Class III medical device designed to harvest and centrifuge autologous bone marrow and blood, extracting concentrated live cells for reinfusion into the body. The product, approved in China and Japan, has established REV-MED as a leader in regenerative medical innovation.
Advanced Devices on Display
Growth and Future Directions
REV-MED reported approximately KRW 10 billion ($7.5 million) in revenue for 2023, with 80% generated from international markets. The company is preparing to globally launch its Novastem anti-aging brand, alongside new technologies such as plasma-based orthopedic and aesthetic devices and ultrasound-powered lifting equipment.
A Vision for Innovation
A REV-MED representative stated, “Our participation in KIMES highlights our commitment to innovation in medical devices. Through challenges and unity, our team has achieved significant milestones, laying the groundwork for REV-MED to grow into a global leader.”
About KIMES: Since its inception in 1980, KIMES has been a driving force for the Korean medical industry, showcasing advancements in medical information systems, ultrasound devices, radiology, AI, robotics, and rehabilitation technologies.
Source: AVING (https://kr.aving.net)